Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR‑9

Abstract

Curcumol has been reported to exert anti‑tumor activity, but its intrinsic molecular mechanism in prostate cancer remains to be elucidated. The present study aimed to analyze the effect of curcumol on prostate cancer and identify its possible internal regulatory pathway using <i>in vitro</i> cell culture and <i>in vivo</i> tumor model experiments. The cytotoxicity of curcumol was detected using a Cell Counting Kit‑8 assay and it was found that curcumol had no obvious toxicity or side effects on RWPE‑1 cells. Wound healing, Transwell and flow cytometry assays demonstrated that curcumol could affect the activity of PC3 cells. The luciferase reporter assay also indicated that microRNA (miR)‑9 could directly target pyruvate dehydrogenase kinase 1 (PDK1). After PC3 cells were transfected with miR‑9 inhibitor or treated with curcumol, the expression levels of the PDK1/AKT/mTOR signaling pathway‑related proteins [PDK1, phosphorylated (p)‑AKT and p‑mTOR] were increased or decreased, respectively. Next, the prostate cancer cell xenograft model was established. Tumor size and the expression levels of PDK1/AKT/mTOR signaling pathway‑related factors were altered following treatment with curcumol. The <i>in vitro</i> and <i>in vivo</i> experiments collectively demonstrated that curcumol could inhibit the PDK1/AKT/mTOR signaling pathway by upregulating the expression level of miR‑9. The present study found that curcumol regulates the PDK1/AKT/mTOR signaling pathway via miR‑9 and affects the development of prostate cancer. These findings could provide a possible scientific insight for research into treatments for prostate cancer.